Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation

Brachytherapy

Volumn 12, Issue 6, 2013, Pages 589-595

  Le Fur, Emmanuelle ^a,b,c   Malhaire, Jean Pierre ^a   Nowak, Emmanuel ^d   Rousseau, Benoit ^d   Erauso, Antoine ^d   Pene Baverez, Dominique ^a   Papin, Grégory ^d   Delage, Francky ^d   Perrouin Verbe, Marie Aimée ^d   Fournier, Georges ^b,d,e   Pradier, Olivier ^a,b,c   Valeri, Antoine ^b,d,e  

^a CHU MORVAN   (France)

^b FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

^c Universite de Bretagne Occidentale   (France)

^d BREST UNIVERSITY HOSPITAL   (France)

^e HÔPITAL TENON   (France)

Author keywords

Brachytherapy; Learning curve; Morbidity; Prostate cancer

Indexed keywords

IODINE 125;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; BRACHYTHERAPY IMPLANT; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; OUTCOME ASSESSMENT; PERMANENT PROSTATE BRACHYTHERAPY; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RADIATION DOSE; RADIATION ONCOLOGIST; SCORING SYSTEM; ULTRASOUND; URINE RETENTION; UROLOGIST;

BRACHYTHERAPY; LEARNING CURVE; MORBIDITY; PROSTATE CANCER;

ADULT; AGED; BRACHYTHERAPY; CONSTIPATION; DEFECATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RECTUM; RETROSPECTIVE STUDIES; URINARY BLADDER; URINARY RETENTION; URINATION; YOUNG ADULT;

EID: 84887614234     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2013.04.002     Document Type: Article

References (47)

1. Davis B.J., Horwitz E.M., Lee W.R., et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012, 11:6-19.
2. Vigneri P., Herati A.S., Potters L. The second decade of prostate brachytherapy: Evidence and cost based outcomes. Urol Oncol 2010, 28:86-90.
3. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
4. Fisher C.M., Troncoso P., Swanson D.A., et al. Knife or needles? A cohort analysis of outcomes after radical prostatectomy or brachytherapy for men with low- or intermediate-risk adenocarcinoma of the prostate. Brachytherapy 2012, 11:429-434.
5. Klein E.A., Ciezki J., Kupelian P.A., et al. Outcomes for intermediate risk prostate cancer: Are there advantages for surgery, external radiation, or brachytherapy?. Urol Oncol 2009, 27:67-71.
6. Potters L., Klein E.A., Kattan M.W., et al. Monotherapy for stage T1-T2 prostate cancer: Radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 2004, 71:29-33.
7. Shah C., Lanni T.B., Ghilezan M.I., et al. Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low/intermediate prostate cancer. Brachytherapy 2012, 11:441-445.
8. Berry D.L., Halpenny B., Hong F., et al. The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: Amulti-center randomized trial. Urol Oncol 2011.
9. Barocas D.A., Mitchell R., Chang S.S., et al. Impact of surgeon and hospital volume on outcomes of radical prostatectomy. Urol Oncol 2010, 28:243-250.
10. Ou Y.C., Yang C.R., Wang J., et al. The learning curve for reducing complications of robotic-assisted laparoscopic radical prostatectomy by a single surgeon. BJU Int 2011, 108:420-425.
11. Patel V.R., Tully A.S., Holmes R., et al. Robotic radical prostatectomy in the community setting-The learning curve and beyond: Initial 200 cases. J Urol 2005, 174:269-272.
12. Secin F.P., Savage C., Abbou C., et al. The learning curve for laparoscopic radical prostatectomy: An international multicenter study. JUrol 2010, 184:2291-2296.
13. Vickers A.J., Savage C.J., Hruza M., et al. The surgical learning curve for laparoscopic radical prostatectomy: A retrospective cohort study. Lancet Oncol 2009, 10:475-480.
14. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001, 51:31-40.
15. Bladou F., Salem N., Simonian-Sauve M., et al. Prog Urol 2004, 14:345-352. French.
16. Hoinkis C., Hakenberg O.W., Lehmann D., et al. Evaluation of dose-volume histograms after prostate seed implantation. 4-Year experience. Strahlenther Onkol 2004, 180:550-556.
17. Merrick G.S., Grimm P.D., Sylvester J., et al. Initial analysis of Pro-Qura: A multi-institutional database of prostate brachytherapy dosimetry. Brachytherapy 2007, 6:9-15.
18. Lee W.R., deGuzman A.F., Bare R.L., et al. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: Evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys 2000, 46:83-88.
19. Taussky D., Moumdjian C., Larouche R., et al. Seed migration in prostate brachytherapy depends on experience and technique. Brachytherapy 2012, 11:452-456.
20. Storey M.R., Landgren R.C., Cottone J.L., et al. Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-Year tumor control and morbidity. Int J Radiat Oncol Biol Phys 1999, 43:565-570.
21. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996, 14:449-453.
22. Mabjeesh N.J., Chen J., Stenger A., et al. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy. Urology 2007, 70:548-553.
23. Keyes M., Schellenberg D., Moravan V., et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys 2006, 64:825-834.
24. Elshaikh M.A., Angermeier K., Ulchaker J.C., et al. Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. Urology 2003, 61:152-155.
25. Cosset J.M., Gomme S., Peiffert D., et al. Cancer Radiother 2007, 11:206-213. French.
26. Vijverberg P.L., Blank L.E., Dabhoiwala N.F., et al. Analysis of biopsy findings and implant quality following ultrasonically-guided 125I implantation for localised prostatic carcinoma. Br J Urol 1993, 72:470-477.
27. Blasko J.C., Ragde H., Grimm P.D. Transperineal ultrasound-guided implantation of the prostate: Morbidity and complications. Scand J Urol Nephrol Suppl 1991, 137:113-118.
28. Zelefsky M.J., Yamada Y., Cohen G.N., et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2007, 67:65-70.
29. Eckman M.H., Ying J., Hertzfeld K., et al. Longitudinal analysis of genitourinary and bowel symptoms in prostate cancer patients following brachytherapy. Am J Clin Oncol 2010, 33:1-10.
30. Chen A.B., D'Amico A.V., Neville B.A., et al. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 2006, 24:5298-5304.
31. Stock R.G., Stone N.N., Lo Y.C., et al. Postimplant dosimetry for (125)I prostate implants: Definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys 2000, 48:899-906.
32. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995, 32:219-225.
33. Crook J., Fleshner N., Roberts C., et al. Long-term urinary sequelae following 125iodine prostate brachytherapy. J Urol 2008, 179:141-145.
34. Gelblum D.Y., Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000, 48:119-124.
35. Pal R.P., Bhatt J.R., Khan M.A., et al. Prostatic length predicts functional outcomes after iodine-125 prostate brachytherapy. Brachytherapy 2011, 10:107-116.
36. Eapen L., Kayser C., Deshaies Y., et al. Correlating the degree of needle trauma during prostate brachytherapy and the development of acute urinary toxicity. Int J Radiat Oncol Biol Phys 2004, 59:1392-1394.
37. Heysek R.V., Gwede C.K., Torres-Roca J., et al. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy 2006, 5:244-250.
38. Saibishkumar E.P., Borg J., Yeung I., et al. Loose seeds vs. stranded seeds: A comparison of critical organ dosimetry and acute toxicity in (125)I permanent implant for low-risk prostate cancer. Brachytherapy 2008, 7:200-205.
39. Aaltomaa S.H., Kataja V.V., Lahtinen T., et al. Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy-Morbidity and outcome results. Radiother Oncol 2009, 91:213-216.
40. Mitchell D.M., Mandall P., Bottomley D., et al. Report on the early efficacy and tolerability of I(125) permanent prostate brachytherapy from a UK multi-institutional database. Clin Oncol 2008, 20:738-744.
41. Neill M., Studer G., Le L., et al. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry. Brachytherapy 2007, 6:173-179.
42. Salem N., Simonian-Sauve M., Rosello R., et al. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: A phase 2 study. Radiother Oncol 2003, 66:159-165.
43. Borchers H., Pinkawa M., Donner A., et al. Rectourethral fistula following LDR brachytherapy. Urol Int 2009, 82:365-366.
44. Stone N.N., Cesaretti J.A., Rosenstein B., et al. Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?. Brachytherapy 2010, 9:114-118.
45. Stone N.N., Stock R.G. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 2007, 69:338-342.
46. Tran A., Wallner K., Merrick G., et al. Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 63:150-154.
47. Keyes M., Spadinger I., Liu M., et al. Rectal toxicity and rectal dosimetry in low-dose-rate iodine-125 permanent prostate implants: A long-term study in 1006 patients. Brachytherapy 2012, 11:199-208.